Financial Support

Contact us directly at:
866.547.0644 8 AM to 8 PM ET, Monday through Friday
To ask about distribution, please email:

Direct support for your patients

Kineret ON TRACK® offers access and reimbursement support to help patients access KINERET. Kineret ON TRACK® provides information regarding patient healthcare coverage options and financial assistance that may be available to help patients with financial needs.

Contact us directly at:
866.547.0644 8 AM to 8 PM ET, Monday through Friday To ask about distribution, please email:
Icon of money dropping into a hand

Patient Assistance Offerings

Kineret ON TRACK® can provide information about potential programs and patient assistance options that may be available to patients. These offerings include:

  • KINERET Copay Assistance Program* is for eligible patients who have commercial prescription insurance. Patients may pay as little as $0 per prescription and receive up to a maximum of $13,000 per calendar year. Click here to enroll your patients
  • KINERET Patient Assistance Program† provides KINERET at no cost to patients who meet eligibility requirements

*In order to participate in the KINERET Copay Assistance Program (Program), a patient must have commercial prescription insurance for KINERET. The Program is not valid for patients whose prescription claims are reimbursed, in whole or in part, by any state or federal government program, including but not limited to Medicaid, Medicare, Medigap, Department of Defense (DoD), Veterans Affairs (VA), TRICARE, Puerto Rico Government Insurance, or any state patient or pharmaceutical assistance program. This offer is not valid for cash-paying patients. The Program is void where prohibited by law. Certain rules and restrictions apply. Sobi reserves the right to revoke, rescind, or amend this offer without notice. This Program is not insurance.
 †Program subject to eligibility requirements and program terms and conditions.

As little as $0 copay icon
Icon of 3 figures with circles above their heads

Direct Support for Your Patients

Dedicated Case Managers are available to help support you and your patients.

Case Managers can:

  • Evaluate a patient’s prescription coverage, including benefits investigation, prior authorization, and appeals assistance support
  • Identify potential financial assistance options that may be available to help patients with financial needs
  • Answer logistical questions and provide information and coordination around the specialty pharmacy fulfillment process
Nurse icon

Treatment Administration Assistance

KINERET Trained Nurses can help your patients understand how to use KINERET, with your direction.

Nurse services include:

  • One-on-one injection training and in-home or virtual visits
  • Tips to help address common injection site reactions
  • Advice on injection site rotation and tracking
  • Helpful insights on issues from medication storage to travel
Prescription delivery truck icon

KINERET Specialty Pharmacy Delivery Service

KINERET Pharmacy Specialists will deliver your patients' prescriptions' right to their doors.

Specialty Pharmacy services include:

  • Prescription delivery directly to patients' homes
  • Ancillary supplies needed for injection
  • Refill reminders
  • Emergency shipments (if applicable and eligible)
  • Information about KINERET
PREVIOUS:   Dosing Calculator
NEXT:   Resources
Important Safety Information
INDICATIONS

KINERET® (anakinra) is an interleukin-1 receptor antagonist indicated for:

Rheumatoid Arthritis (RA). Reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease-modifying antirheumatic drugs (DMARDs)

Cryopyrin-Associated Periodic Syndromes (CAPS). Treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID)

Deficiency of Interleukin-1 Receptor Antagonist (DIRA). Treatment of Deficiency of Interleukin-1 Receptor Antagonist (DIRA)

CONTRAINDICATION

KINERET is contraindicated in patients with known hypersensitivity to E. coli–derived proteins, KINERET, or to any components of the product

IMPORTANT SAFETY INFORMATION

Serious Infections. In RA, discontinue use if serious infection develops. In KINERET-treated NOMID or DIRA patients, the risk of a disease flare when discontinuing KINERET treatment should be weighed against the potential risk of continued treatment. Do not initiate KINERET in patients with active infections

Use in combination with Tumor Necrosis Factor (TNF)-blocking agents is not recommended

Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported. Patients with DIRA may have an increased risk of allergic reactions, particularly in the first several weeks after starting KINERET treatment

Immunosuppression. The impact of treatment with KINERET on active and/or chronic infections and the development of malignancies is not known

Immunizations. Live vaccines should not be given concurrently with KINERET

Neutrophil counts should be assessed prior to initiating KINERET treatment, and while receiving KINERET, monthly for 3 months, and thereafter quarterly for a period up to 1 year

Serious Adverse Reactions

RA: The most serious adverse reactions were: Serious Infections and Neutropenia, particularly when used in combination with TNF blocking agents.

NOMID and DIRA: The most serious adverse events were infections.

Most Common Adverse Reactions

RA: The most common adverse reactions (incidence ≥ 5%) are injection site reaction, worsening of rheumatoid arthritis, upper respiratory tract infection, headache, nausea, diarrhea, sinusitis, arthralgia, flu-like symptoms, and abdominal pain

NOMID: The most common AEs during the first 6 months of treatment (incidence > 10%) are injection site reaction, headache, vomiting, arthralgia, pyrexia, and nasopharyngitis

DIRA: The most common AEs are upper respiratory tract infections, rash, pyrexia, influenza-like illness, and gastroenteritis

Post-marketing Experience

Hepato-biliary disorders (elevations of transaminases; non-infectious hepatitis) and thrombocytopenia, including severe thrombocytopenia have been identified during postapproval use of KINERET. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

These are not all the possible risks associated with KINERET. Please see Full Prescribing Information for KINERET at https://www.KineretRxHCP.com/home.php
To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or FDA at 1-800-FDA-1088
Click here for full Prescribing Information for KINERET.